DarshanTalks Podcast

Send us Fan Mail

 Mayya Tatsene has been issued a final debarment order by the FDA. The reason for the debarment stems from violating FDA regulations concerning clinical trials. Specifically, Tatsene failed to test on the appropriate number of subjects, thus compromising the integrity and reliability of the trial data. How to Avoid this Fate: To sidestep such consequences, individuals and organizations must strictly adhere to FDA guidelines, which include rigorous clinical trial protocols like proper sample sizes for testing. Failing to do so could result in severe penalties, including debarment. Impact: This action sets a precedent that has significant implications for clinical researchers and Contract Research Organizations (CROs). Not only does it tarnish reputations but it also raises questions about data integrity, potentially delaying drug approvals and harming patients in the long run. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 The FDA's Center for Tobacco Products (CTP) was created in 2009 to regulate tobacco products. Micah Berman worked at CTP from 2011-2012. He discusses the CTP's evolution in the past decade and shares insights from his recent article published in the New England Journal of Medicine. We discussed the following: 

• When was Micah a part of CTP? - 0:58 - 1:27 
• What was the vision behind CTP's creation? - 1:35 - 4:48 
• What caused CTP to be created? / The background of how CTP was established – 5:07 – 12: 33 
• What was the reasoning behind the tobacco industry's move to be regulated by the FDA? – 12:35 – 17:16 
• What challenges did the FDA and CTP encounter when they first started regulating cigarettes, and how does the situation compare in 2023? – 17:17 – 25:19 
• Can the FDA shut down the entire tobacco industry? – 25:20 – 27: 30 
• How can the FDA, with its authority over tobacco product regulation, improve public health? – 27:31– 29:33 
• Micah talks about his article: 29:33 – 34:50 
• What should the FDA focus on while regulating tobacco products/cigarettes? – 34:57 – 40:08 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 Darshan Kulkarni emphasizes that companies considering #acquisitions must be ready for scrutiny from multiple agencies: FDA, FTC, DOJ, and OIG. FDA examines various aspects like manufacturing, clinical research, pharmacovigilance, advertising, and distribution. FTC now addresses advertising and antitrust concerns. DOJ concentrates on corporate compliance. Is your organization well-prepared for these assessments? Get in touch with us for more information. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 In this episode, the focus is on planning #FDA meetings and the significance of pre-IND meetings. We discuss how pre-IND meetings are crucial for identifying and addressing any roadblocks or gaps in the preclinical program before the actual filing. By doing so, potential delays or complications during the clinical trial phase can be mitigated. The discussion also includes insights into optimizing dosing strategies in oncology phase two studies, prioritizing patient experience, and finding tolerable doses that allow for extended drug administration. The conversation touches on cultural differences in FDA approval approaches across regions and the collaborative nature of successful FDA meetings. Overall, the episode emphasizes the importance of preparation, data-driven justifications, and effective collaboration to advance drug development and ensure safe treatments for patients. Points discussed: FDA meetings and Pre-IND significance: 1:30- 3:48 Optimizing oncology dosing strategy: 3:49- 8:32 Navigating maximum tolerated dose across cultures: 8:33- 13: 56 Key Indicators to address: 13:57- 15:38 Collaborative FDA meetings: 15:39- 21:59 FDA meeting composition: 22:00- 25:16 Learning from virtual FDA meetings: 25:17- 27:42 Strategic planning for FDA meetings: 27:43- 28:42 #FDAMeetings #FDA #FDAInsights #DrugDevelopment #PatientCentric #FDAapproval #FDAteam patientexperiences #medicalinnovation #patientsafety #clinicaltrials #clinicalresearch #darshantalks #kulkarnilawfirm #dt #klf #recentrecap 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 Isaac Rodriguez-Chavez discusses the role and the significance of the Decentralized Clinical Trials guidance. 
We discuss the following: 

• What are decentralized clinical trials? - 2:05- 4:25 
• What factors led to the rise of decentralized trials? – 4:26- 10:58 
• What is the role of decentralized clinical trials?- 10:59- 14:36 
• What is the process of FDA to develop a guidance?- 14:42- 17:48 

#innovativeapproaches #healthcarerevolution #industryinnovation #hybridapproaches #remotetrials #diversityintrials #patientcentrictrials #inclusiveresearch #clinicaltrials #clinicalresearch #patientempowerment #kulkarnilawfirm #klf #darshantalks #dt #recentrecap 

Sign up for our newsletter- https://darshantalks.com/ Website: http://www.darshantalks.com Law Firm: http://www.kulkarnilawfirm.com Twitter: https://twitter.com/darshantalks LinkedIn: https://www.linkedin.com/in/darshankulkarni/ ---- 

Disclaimers: This discussion is provided for general educational purposes and should not be construed as legal advice, regulatory advice or medical advice. Listening to this video or otherwise depending on discussions in this video do not, in any way, create an attorney attorney-client relationship 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 Istvan Fekete and Darshan Kulkarni discuss the 7 types of clinical trial agreements (CTAs). CTAs Explored Include: 

1.  Industry-Sponsored Trials, 
2. Phase Four and Post-Market Studies, 
3. Registry Studies, 
4. Federally Funded Studies, 
5. Drug and Device Studies, 
6. Consortium Studies, 
7. Investigator-Initiated Studies: 

We discuss the potential risks of seeding trials, and the need for both sponsors and sites to be vigilant about potential fraud and compliance issues.

Discussions include practical advice for both sponsors and sites, encouraging proactive feasibility assessments and streamlined concurrent negotiations.

The conversation underscores the multifaceted nature of clinical trial agreements, underscoring their pivotal role in advancing medical research while ensuring ethical practices and efficient collaborations. Join our discussion between Darshan Kulkarni and Istvan Fekete.

Receive the latest interview updates directly to your inbox by subscribing to our newsletter at https://darshantalks.com/
#clinicaltrialagreements #researchcontracts #ResearchAgreements #compliancematters #medicalbreakthroughs #trialagreementtips #advancingmedicine #regulatoryguidelines #clinicaltrialethics #darshantalks #dt #kulkarnilawfirm #klf

Website: https://www.darshantalks.com/
Law Firm: https://kulkarnilawfirm.com/
Twitter: https://twitter.com/darshantalks

Support the show

www.kulkarnilawfirm.com